- 产品详情
- 产品参数
- 产品评论
R&D CCM012 StemXVivo Serum-Free Tumorsphere Media
产品编号 CCM012| rndsystems
StemXVivo Serum-Free Tumorsphere Media
For Tumorsphere Formation of Human/Mouse/Rat Cancer Cells
产品介绍
Kit Summary
Semi-solid media formulated and optimized for tumorsphere formation.
Key Benefits
Shown to support sphere formation of seven tumor cell lines
Lot-to-lot consistency reduces experimental variability
Specially formulated and optimized for tumorsphere formation
Why Perform the Tumorsphere Assay Using Specially Formulated Media?
Tumorsphere assays, also called sphere-formation assays, are in vitro assays that assess stem cell characteristics of tumor cells. There are a number of variables that contribute to variation in data obtained from tumorsphere assays including the purity of the starting cell population, the type and quantity of media and supplements, and the potential for tumorspheres to aggregate. See Details
Media Components
100 mL of StemXVivo Serum-Free Tumorsphere Media. See Details
Data Examples
Tumorspheres Formed from the MCF-7 Human Breast Cancer Cell Line. MCF-7 human breast cancer cells were suspended in StemXVivo Serum-Free Tumorsphere Media (Catalog # CCM012) containing 2 U/mL Heparin (Tocris Catalog # 2812) and 0.8 μg/mL Hydrocortisone (Tocris, Catalog # 4093). The cells were plated at 3 x 104 cells per well in a 6-well ultralow adhesion culture plate and cultured at 37 °C and 5% CO2 for 3-10 days to induce tumorsphere formation. Tumorspheres were imaged using a CloneSelect™ Imager from Molecular Devices (New Milton) Limited. |
Preparation and Storage
Stability & Storage
Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.
Background: Cancer Stem Cells
As for all stem cells, oncogenically transformed cancer stem cells (CSCs) are defined by their ability for self-renewal and multipotency. The CSC hypothesis states that, although CSCs represent a rare population of cells within a tumor, their high tumorigenic capacity drives tumorigenesis. Due to their intrinsic stem cell-like properties, CSC proliferation generates more CSCs, and all the differentiated cell types that compose the bulk of the tumor. Non-CSCs in the tumor have been shown to proliferate at a faster rate than CSCs, but have little tumor-initiating potential. Because CSCs exhibit increased resistance to toxic and chemical insults, this specific subpopulation of cells is believed to underlie resistance to chemotherapy and disease relapse. In fact, the CSC model posits that all CSCs must be eradicated to eliminate a tumor and prevent its recurrence.
公司简介
R&D Systems作为全球免疫学和细胞生物学产品的领跑者，1976年创立于美国明尼苏达州。其母公司Bio-Techne（原Techne公司）于1983年在美国NASDAQ上市。
目前，R&D Systems拥有近30,000种产品，95%以上由自己研发生产。其产品包括细胞因子、ELISA试剂盒、生长因子、趋化因子、抗体、Animal-Free™蛋白、Luminex 液相芯片、多因子检测固相芯片、流式细胞分析与细胞筛选、干细胞及细胞培养等；覆盖肿瘤、发育、糖生物、内分泌、免疫、神经学、蛋白酶、信号传导等学科研究领域；且每年有近2,000种新产品不断问世，以满足不同科研工作者的研究需要。
Uante,您的科研物资战略合作伙伴！
重庆市寰宇安泰生物科技有限公司
固定电话：023-67946738
全国热线：400-8623-068